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Abstract 
Background: The safety and immunogenicity of PfAMA1, adjuvanted with Alhydrogel® was assessed in malaria–
experienced Malian adults. The malaria vaccine, PfAMA1-FVO [25-545] is a recombinant protein Pichia pastoris-
expressed AMA-1 from Plasmodium falciparum FVO clone adsorbed to Alhydrogel®, the control vaccine was tetanus 
toxoid produced from formaldehyde detoxified and purified tetanus toxin.
Methods: A double blind randomized controlled phase 1 study enrolled and followed 40 healthy adults aged 
18–55 years in Bandiagara, Mali, West Africa, a rural setting with intense seasonal transmission of P. falciparum malaria. 
Volunteers were randomized to receive either 50 µg of malaria vaccine or the control vaccine. Three doses of vac-
cine were given on Days 0, 28 and 56, and participants were followed for 1 year. Solicited symptoms were assessed 
for seven days and unsolicited symptoms for 28 days after each vaccination. Serious adverse events were assessed 
throughout the study. The titres of anti-AMA-1 antibodies were measured by ELISA and P. falciparum growth inhibition 
assays were performed.
Results: Commonest local solicited adverse events were the injection site pain and swelling more frequent in the 
PfAMA1 group. No vaccine related serious adverse events were reported. A significant 3.5-fold increase of anti-AMA-1 
IgG antibodies was observed in malaria vaccine recipients four weeks after the third immunization compared to the 
control group.
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Background
Despite recent renewed malaria control efforts, the dis-
ease still caused in 2013, 438,000 deaths (uncertainty 
range 236,000–635,000), 90  % of which occurred in 
Africa south of the Sahara [1]. An effective malaria vac-
cine would be a valuable additional tool particularly if 
one considers the new impetus towards malaria elimina-
tion [2]. Apical membrane antigen-1 (AMA1) is a surface 
protein expressed during the asexual blood stage of Plas-
modium falciparum, and a leading blood stage vaccine 
candidate, with different formulations assessed and being 
tested in malaria endemic areas in Africa [3–5]. Three 
AMA-1-based vaccines have been evaluated in clinical 
trials in Mali, including two different monovalent vac-
cines based on AMA-1 derived from the 3D7 and FVO 
clones of P. falciparum, respectively, [5] and a bivalent 
vaccine that includes both of these versions of AMA-1 
[6]. Preclinical studies [7, 8] of AMA1-based vaccines as 
well as clinical trials in people not naturally exposed to 
malaria [9, 10] have shown promise.
The trial reported here used PfAMA1-FVO [25-545], 
a lyophilized preparation of the ectodomain of the FVO 
clone of P. falciparum AMA1 [11]. This first phase 1 trial 
in malaria-exposed adults was the logical sequence of 
the clinical development of PfAMA1-FVO [25-545], and 
took place after a phase 1a trial done in Nijmegen [9]. The 
aim was to assess the malaria vaccine candidate immuno-
genicity and reactogenicity in adults naturally exposed to 
malaria in Mali.
Methods
This was a double blind conducted, randomized, con-
trolled clinical trial designed to assess the safety and 
immunogenicity of the blood stage malaria vaccine can-
didate PfAMA1 [25-545] of P. falciparum FVO strain, 
adjuvanted with Alhydrogel®.
Study setting
The study was conducted at the Bandiagara Malaria Pro-
ject (BMP) research clinic located close to the district 
hospital in Bandiagara, a rural setting with 13,634 inhab-
itants in the Dogon country in northeast Mali. Mean 
annual rainfall is 600 mm and Anopheles gambiae is the 
principal malaria vector. Malaria transmission is highly 
seasonal and overlaps with the rainy season [12]. Plas-
modium falciparum is the most frequent parasite species 
causing 97  % of malaria infections. Malaria burden is 
heavy, children aged less than 10  years have an average 
of two clinical malaria episodes every transmission sea-
son [12, 13] and severe malaria afflicts one in 50 children 
aged less than 6 years each year [14]. Older children and 
adults are relatively protected against malaria disease but 
remain susceptible to malaria infection.
Participants
Participants were healthy adult men and women residing 
in Bandiagara aged 18–55 years old. After a screening for 
eligibility they were included if they planned to remain in 
Bandiagara for at least 12 months, showed good general 
health based on history, clinical and laboratory examina-
tions and gave written informed consent. Female volun-
teers had in addition to declare willingness not to become 
pregnant during the first 5 months of the study, and they 
were referred to existing birth control programme at the 
district health care centre. Exclusion criteria were sig-
nificant current illness as indicated by history, examina-
tion and/or laboratory testing including complete blood 
counts, alanine aminotransferase (ALT) and serum cre-
atinine; previous immunization with any experimental 
vaccine; chronic use of immunosuppressants; receipt of 
blood products during the previous 6 months; and allergy 
to substances present in the vaccines.
Ethical clearance
The Institutional Review Board of the University of Bam-
ako Faculty of Medicine approved the protocol and the 
informed consent forms, approval letter 07-35/FMPOS 
dated on May 15, 2007. The informed consent forms 
specified that the trial data will be published and that the 
participants confidentiality will be preserved by using 
only anonymous study numbers and no reference to par-
ticular individual identity. After obtaining community 
permission as described [15], the trial was publicized by 
local radio broadcast. The trial was conducted in compli-
ance with the International Conference on Harmonisa-
tion Good Clinical Practices, the Declaration of Helsinki 
and applicable regulatory requirements of Mali. Separate 
written informed consent was obtained for screening 
and enrolment. Verbal consent of illiterate participants 
was administered and then documented using their fin-
gerprints, a process verified by signatures of independ-
ent witnesses. Permission to import the investigational 
Conclusion: The PfAMA1 showed a good safety profile. Most adverse events reported were of mild to moderate 
intensity. In addition, the vaccine induced a significant though short-lived increase in the anti-AMA1 IgG titres.
Registered on www.clinicaltrials.gov with the number NCT00431808
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products in Mali was given by the Republic of Mali Min-
istry of Health. The trial sponsor was the African Malaria 
Network Trust (AMANET). A safety monitoring com-
mittee set by AMANET reviewed the safety data after 
the first and second vaccine dose and gave authorization 
to administer respectively the second and third vaccine 
doses.
Interventions and participant surveillance
PfAMA1 antigen comprises amino acids 25-545 corre-
sponding to the ectodomain of AMA1 derived from the 
FVO clone of P. falciparum. Vaccine production and for-
mulation are described elsewhere [11]. The vaccine was 
manufactured under GMP conditions by Eurogentec SA, 
Belgium, and supplied as lyophilized single dose vials 
containing 62.5 µg AMA1 protein, 23.3 µg EDTA, 25 mg 
saccharose, 187  µg NaH2PO4·2H2O, 226  µg Na2HPO4. 
The adjuvant used, Alhydrogel® is a crystalline alu-
minium oxyhydroxide AlOOH, also known as boehmite 
supplied as a 0.2  % suspension by Staten Serum Insti-
tute (SSI), Denmark. Vials were reconstituted by adding 
625 µL 0.2 % Alhydrogel® suspension; the adsorption to 
Alhydrogel® was previously confirmed to be greater than 
99  %. The reconstituted vaccine was then incubated for 
60  min at room temperature to facilitate adsorption to 
the Alhydrogel® and a dose of 0.5  mL containing 50  µg 
AMA1 and approximately 0.5  mg aluminium was used 
for injection.
The control vaccine, tetanus toxoid was also manu-
factured at SSI. The tetanus toxoid was produced from 
a formaldehyde detoxified and purified tetanus toxin. 
The vaccine was supplied in pre-filled syringes of 0.5 mL 
containing more than 20  IU tetanus toxoid, aluminum 
hydroxyde as adjuvant and thiomersal as preservative. A 
buffer solution, water for injection, was added. All doses 
of all vaccines were administered by intramuscular injec-
tion in the left deltoid muscle.
The study vaccines were given on study days 0, 28 and 
56, the first vaccine dose being injected in May 2007. 
Study day 84 clinic visit was done in August, at the peak of 
malaria transmission. Study day 140 clinic visit took place 
at the height of the dry season. The final study follow-
up on day 365 coincided with the beginning of the 2008 
malaria season. Interim safety reports were reviewed 
by an independent safety monitoring committee before 
the second and third vaccine doses. Active surveillance 
of participants for 28 days after each immunization was 
completed in August 2008 corresponding to study day 
84. The database was locked for the primary unblinded 
analysis after study day 84, and the study continued in a 
single-blinded fashion, although individual study alloca-
tions were not disclosed to on-site study investigators or 
staff with the exception of the principal investigator. The 
extended surveillance phase included continuous access 
to free basic medical care at the research clinic, monthly 
home visits, and scheduled visits on study days 140 and 
364. All participants completed the follow-up schedule 
and were included in the analysis.
Outcomes
The primary outcome was safety, measured through the 
occurrence of solicited symptoms during a 7-day follow-
up period after immunization (day of immunization and 
days 1, 3 and 7 after immunization); the occurrence of 
unsolicited symptoms during a 28-day follow-up period 
after immunization (day of immunization and 28 sub-
sequent days); the occurrence of laboratory toxicities; 
and the occurrence of serious adverse events during the 
entire study period. Secondary outcomes measured titres 
of anti-AMA1 antibody (IgG) by ELISA and activity of 
anti-AMA1 antibody by growth inhibition assay (GIA). 
These assays were performed at baseline and at specified 
times during and after immunization (Additional file 1).
Safety assessment
Following each immunization, participants were directly 
observed for 30 min, and then evaluated at the study clinic 
1, 3, 7 and 14 days after each immunization and on study 
days 84, 140 and 364. Starting on day 140, monthly home 
visits were made to check the health status of participants 
and to encourage them to come to the research clinic if 
they felt ill. Clinical evaluations consisted of measure-
ment of vital signs and assessment for local injection site 
and general solicited signs or symptoms. Local signs and 
solicited symptoms included pain, swelling, erythema at 
the injection site and limitation of arm abduction at the 
shoulder. General signs and solicited symptoms included 
fever (oral temperature  ≥37.5  °C), chills, nausea, head-
ache, malaise, myalgia and joint pain. Any other signs or 
symptoms were considered to be unsolicited, as were all 
signs or symptoms that occurred more than 7 days after 
immunization. All solicited local symptoms were consid-
ered related to the study vaccines. Pregnancies were mon-
itored throughout the 12-month study period and until 
delivery, when this occurred after the study end. Blood 
was collected at screening, on immunization days and 
7 days after each immunization and on study days 84, 140 
and 364 to determine Complete blood count, biochemis-
try parameters (serum potassium, sodium, ASAT, ALAT, 
total bilirubin, alkaline phosphatase, γGT and creatinine). 
Adverse events were judged for relatedness to study vac-
cines and graded by severity as shown in Additional file 2: 
Table  I. Laboratory parameters intensity was graded as 
indicated in Additional file 3: Table II.
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Immunogenicity assessment
Antibody responses to AMA-1 were measured by an 
enzyme-linked immunosorbent assay (ELISA). Briefly, 
IgG ELISAs were performed using PfAMA-1 FVO [25-
545] from the same clinical batch which production was 
described by Faber et al. [9] and that was used in a Phase 
1a trial in Nijmegen [11], as the capture antigen, in serial 
twofold dilution, and one arbitrary unit (AU) was defined 
at an optical density of 1.0 over background. Thus the 
titre in AU represents the dilution of the serum required 
to obtain an OD of 1 over background. Antibody 
responses were measured on serum obtained from par-
ticipants at the time of each immunization (study days 0 
[baseline]), 28, 56, 84, 140 and 364.
Pre-immunization (day 0) sera and sera from 4 weeks 
after the third immunization (day 84, corresponding to 
peak antibody titres) were tested for growth inhibitory 
effects against homologous parasites expressing AMA1 
(derived from FVO clone) P. falciparum line as described 
[16, 17]. Antibodies used for growth inhibition assays 
were purified on protein G columns (Sigma, St Louis, 
MO) using standard protocols, exchanged into RPMI 
1640 using Amicon Ultra-15 concentrators (30 kDa cut-
off, Millipore, Ireland), filter-sterilized and stored at 
−20  °C until use. IgG concentrations were determined 
using a Nanodrop ND-1000 spectrophotometer (Nan-
odrop Technologies, Wilmington, DE, USA).
Plasmodium falciparum strain FCR3 was cultured 
in vitro using standard P. falciparum culture techniques 
in an atmosphere of 5 % CO2, 5 % O2 and 90 % N2. FCR3 
AMA1 (accession no. M34553) differs by 1 amino acid 
in the pro-sequence from FVO AMA1 (accession no. 
AJ277646).
The effect of 5 or 10 mg mL−1 purified IgG antibodies 
on parasite invasion was evaluated in triplicate using 96 
well flat-bottomed plates (Greiner) with in vitro matured 
and synchronized P. falciparum schizonts at a starting 
parasitaemia of 0.2–0.4  %, a haematocrit of 2.0  % and 
a final volume of 50 µL containing 10 % normal human 
serum, 20  µg  mL−1 gentamicin in RPMI 1640. After 40 
to 42 h, cultures were resuspended, and 50 µL was trans-
ferred into 200 µL ice-cold PBS. The cultures were then 
Table 1 Baseline characteristics at enrolment
GMT geometric mean titre in arbitrary units (AU), CI confidence interval, ALT 






Mean age in year ± SD 30.1 ± 10.6 26 ± 10.5 ns
Female (%) 70 65 ns
Mean WBC 103/µL ± SD 6.0 ± 1.3 6.4 ± 1.4 ns
Mean RBC 103/µL ± SD 4.6 ± 6 4.7 ± .4 ns
Mean Hemoglobin ± SD 13.3 ± 1.8 13.0 ± 1.2 ns
Mean Platelets103/µL ± SD 245.2 ± 64.8 255.2 ± 76.0 ns
Mean Lymphocytes 103/
µL ± SD
2.6 ± 0.6 2.9 ± 0.8 ns
Mean Creatinin µM/l ± SD 62.7 ± 13.8 53.3 ± 5.5 ns
Mean ALT U/L ± SD 14.5 ± 5.5 12.7 ± 5.6 ns








Table 2 Signs and solicited symptoms during the 7-day follow-up periods after each immunization













Overall Severe Overall Severe Overall Severe Overall Severe Overall Severe Overall Severe
Local
 Pain (%) 12 (0.60) 0 9 (0.45) 0 6 (0.30) 0 8 (0.40) 0 2 (0.10) 0 2 (0.10) 0
 Limited arm motion (%) 1 (0.05) 0 1 (0.05) 0 0 0 1 (0.05) 0 0 0 0 0
 Swelling (%) 7 (0.35) 2 (0.10) 8 (0.40) 4 (0.20) 7 (0.35) 2 (0.10) 1 (0.05) 0 2 (0.10) 0 9 (0.45) 1 (0.05)
 Erythema (%) 0 0 1 (0.05) 0 0 0 0 0 0 0 0 0
Systemic
 Fever (%) 2 (0.10) 0 0 0 0 0 1 (0.05) 0 3 (0.15) 0 1 (0.05) 0
 Headaches (%) 5 (0.25) 0 6 (0.30) 0 3 (0.15) 0 10 (0.50) 4 (0.20) 0 1 (0.05) 0
 Joint pain (%) 1 (0.05) 0 0 0 0 0 1 (0.05) 0 0 0 1 (0.05) 0
 Malaise (%) 1 (0.05) 0 0 0 0 0 3 (0.15) 0 0 0 0 0
 Myalgia (%) 2 (0.10) 0 4 (0.20) 0 1 (0.05) 0 2 (0.10) 0 0 0 0 0
 Nausea (%) 3 (0.15) 0 0 0 0 0 1 (0.05) 0 0 0 0 0
 Chills (%) 1 (0.05) 0 0 0 0 0 1 (0.05) 0 0 0 0 0
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centrifuged, the supernatant removed and the plates 
were frozen. Inhibition of parasite growth was estimated 
using the pLDH assay as previously described [16]. Para-
site growth inhibition, reported as a percentage, was cal-
culated as follows: 100 − ((Odexperimental − Od background)/
(Odcontrol  −  Odbackground)  ×  100). Control IgG was iso-
lated from malaria naïve donors. The AMA1 expressed 
was verified to be FCR3 by RFLP analysis and parasite 
cultures used for GIA tested negative for Mycoplasma by 
PCR.
Sample size
Determination of sample size was based on the pri-
mary safety endpoint, i.e. the occurrence of any solic-
ited adverse events, unsolicited adverse events or change 
from baseline values of biological parameters during the 
study period. The primary analysis population was the 
intent-to-treat (ITT) population. Power calculations were 
based on the exact binomial distribution. With a sample 
size of 20 participants in each group, the study is pow-
ered to detect at least one adverse event or change from 
baseline values of biological parameters with a probabil-
ity of at least 90 % if the incidence rate of adverse event 
or change from baseline values of biological parameters 
is 10.9 % or more. The study have a power of at least 80 % 
and 95 % to detect at least one adverse event or change 
from baseline values of biological parameters if their inci-
dence rates are 7.7  % and 13.9  % or more, respectively. 
Incorporation of a comparator vaccine group of 20 per-
mitted broad initial estimates of the incidence of local 
and general side effects and of immune responses among 
vaccine recipients.
Randomization and masking
Individual participants were randomized in a 1:1 ratio to 
receive either PfAMA1-FVO/Alhydrogel® or tetanus tox-
oid at the time of vaccination. Randomization to either of 
the two vaccines was done using a computer-generated 
randomization list. The randomization list contained 
sequential codes that linked a study number to a vaccine 
assignment. Study numbers were assigned to participants 
of each group in the order in which they were enrolled 
in the trial. The PfAMA1 vaccine and the comparator 
had different appearances. Therefore the vaccine prepa-
ration area was separated from the vaccine administra-
tion area. Vaccinations were carried out simultaneously 
in two separate consultation rooms, which were con-
nected to a central pharmacy (the vaccine preparation 
room) by small windows with a sliding closure. On vac-
cination days, the prepared syringe was handed through 
the small window to a vaccinator for vaccine administra-
tion. In addition a study nurse not involved with assess-
ment of study outcomes administered vaccines. And 
finally, the syringe containing vaccine was covered with 
opaque tape to mask its content and labelled with the 
participant study number and randomization code. At 
the study site, only the pharmacist, pharmacy assistant 
and the drug manager had access to the randomization 
list. Participants, investigators, lab personnel and all staff 
performing follow-up evaluations were blinded as to vac-
cine assignment. Following vaccine administration, par-
ticipants were assessed and follow-up visits conducted by 
clinicians who had not been involved in the vaccinations.
Data analysis
Data quality assurance
The trial was conducted in compliance with BMP Clini-
cal Trial Quality Assurance Procedures and the MRTC 
Clinical Laboratory Quality Assurance Plan. The study 
sponsor ensured the external monitoring of the trial. Fol-
lowing the pre study assessment, study initiation, three 
routine monitoring and closeout visits were performed 
during the trial. Standard Case Report Forms pages mon-
itored and validated were sent to MRTC Data Manage-
ment Unit for data entry into a GCP compliant database. 
Data was double entered by two independent data entry 
clerks and then reconciled by the study statistician. After 
resolution of all discrepancies, the database was frozen 
and used for analysis.
Statistical methods
For all safety endpoints, adverse events (AEs) were sum-
marized by grade and vaccine doses for each vaccination 
group. Categorical data are summarized using counts 
and percentages. For immunogenicity analysis, ELISA 
titres of AMA1 antibodies are plotted by vaccine group 
and time points together with the 95 % CI bars.
Comparisons of proportions between vaccine groups 
were done using Fisher exact test and Wilcoxon-Mann–
Whitney test was used for comparison of distributions 
of ordinal or continuous data. Comparisons between 
baseline level and post-vaccination level of biological 
parameters were done using McNemar change test (for 
categorical data) or Wilcoxon signed ranks test (for ordi-
nal or continuous data). Analysis of Mean Fold Increase 
(MFI) was done using a Pearson’s product moment cor-
relation (r) and the slope and intercept were estimated 
using linear regression. The significance of the correla-
tion coefficient was assessed by a t test. All tests were 
2-sided, and no correction of p-values was made for addi-
tional analyses.
Results
Participant flow and baseline data
Ninety participants were screened, 40 were enrolled (26 
females and 14 males) and all received the first dose of 
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the vaccine according to study allocation (Fig. 1). Com-
mon reasons for exclusion were concurrent illnesses, 
laboratory abnormalities during screening. The mean 
age was 30.1 years in the malaria vaccine group and 26.0 
in the control group. In the PfAMA1 group two partici-
pants were excluded from vaccination after the second 
dose; one because of urticaria deemed to be possibly 
related to vaccine due to time relationship and the sec-
ond because of pruritis of unknown cause. In the tetanus 
toxoid group, one participant was excluded from vacci-
nation after having developed a swelling of the upper lip 
post dose 1 and a history known only after inclusion, of 
allergy to peanuts. The two groups were generally simi-
lar at enrolment with regard to gender, age or laboratory 
parameters (Table 1). 
Safety and reactogenicity
Overall, the products showed a good safety profile simi-
lar to observations reported from previous trials. The 40 
participants experienced a total of 257 adverse events, 
136 were solicited AEs and 121 were unsolicited AEs. 
Additional vaccine doses did not globally increase the 
number of AEs.
Local solicited adverse events
In the PfAMA1 group the most frequent local solicited 
AE was injection site pain reported at least by 60 % of the 
participants after any dose (Table 2) as compared to 40 % 
in the control group. All cases of injection site pain were 
of mild to moderate intensity and resolved within three 
days post-vaccination. Second in frequency was swell-
ing at the injection site observed at least in 45 % of the 
participants after any of the vaccine dose. Injection site 
swelling was the only solicited AEs with grade 3 inten-
sity. The grade 3 swelling was defined as a diameter supe-
rior to 50 mm and was not associated with pain or with 
other functional impairments. The incidence of local 
solicited AEs did not increase with subsequent vaccine 
dose administration. In the tetanus toxoid group, fre-
quency of injection site pain and swelling was more bal-
anced between participants, with most of events having 
a mild to moderate intensity (Table  2). One participant 
had grade 3 swelling that resolved within the three days 
of follow up.
Systemic solicited adverse events
All solicited systemic AEs were of minor (93.5  %) or 
moderate (6.5 %) intensity and consisted mainly of head-
ache and myalgia. There was no appreciable difference 
between the two groups though the control group experi-
enced double the number of headaches after dose 1.
Unsolicited adverse events
Overall participants had a total of 123 unsolicited adverse 
events; 58 occurred in the malaria vaccine group and 65 
in the control group. Unsolicited AEs classified by Body 
system and WHO preferred terms consisted mainly of 
respiratory disorders and infections, and were balanced 
by groups, being a representative picture of the morbidity 
usually observed in the study area.
One case of injection site induration of moderate 
intensity causally related to vaccine was reported in the 
malaria vaccine group after the second dose. The indura-
tion resolved within 4 weeks and the participant received 
the third vaccine dose. Three instances of pregnancy were 
reported, all after the study day 84. One case occurred in 
the control group and the participant decided to inter-
rupt her pregnancy by abortion at the age of 4  weeks. 
Two others cases occurred in the malaria vaccine group; 
in both situations the pregnancy was diagnosed close to 
the last study clinic visit on study days 225 and 364. Both 
pregnancies resulted in healthy babies, one girl and one 
boy.
Serious adverse event
One serious adverse event occurred in one partici-
pant in the tetanus toxoid group on study day 94. The 
diagnosis was an acute episode of food poisoning that 
resolved without sequelae. The event was not related to 
vaccination.
Laboratory safety tests
Overall, the results showed a good biological safety pro-
file. Only minor laboratory anomalies were reported and 
those consisted of grade 1 high Bilirubin levels in the 
malaria vaccine group after the first dose. These values 
returned to normal ranges before the second dose. There 
was no difference in mean haemoglobin levels between 
the two groups. No episode of anaemia defined as hae-
moglobin level ≤9.5 g/dL was observed among both vac-
cines recipients. The lowest haemoglobin level was 9.7 g/
dL, recorded in a female participant on study days 35 and 
84, in the malaria vaccine group.
Immunogenicity
IgG antibody levels to the FVO-AMA1 antigen are 
depicted in Figs. 2 and 3, and summary statistics are tabu-
lated in Table 3. Baseline levels of anti-AMA1 antibodies 
were high in both groups and were higher in the tetanus 
toxoid group as compared to the PfAMA1 group; 5164, 
95  % CI (2494 to 10,691) versus 9938, 95  % CI (4484 to 
22,025), respectively. The PfAMA1 vaccine induced a sig-
nificant increase in AMA1-specific IgG (i.e., ratio day 
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Population screened (n= 90)
Excluded (n= 50)












Case#1: Generalized urticaria post 
vaccination 2
Case#2: Mixed vaccination: Tetanus 





Did not receive allocated intervention 
(n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=2)
Give reasons:
Case#1: lip swelling after first dose and 
reported peanut allergy
Case#2: social problems with the 
husband due to participation in the study














Fig. 1 Trial profile
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x/baseline  >1) at all time points following vaccination 
(p  <  0.05) (Table  3); after vaccination, titres increased 
gradually in the PfAMA1 recipients until day 84 when 
a maximum level was observed with a geometric mean 
of 17,584 arbitrary units 95  % CI (9889 to 31,267). The 
PfAMA1 group showed a 3.5, 95 % CI (2.3–5.4) fold rise 
in the IgG titres by day 84 as compared to baseline levels, 
while in the control group the day 84 fold rise compared to 
baseline was 1.07, 95 % CI (0.7–1.6). Thereafter, IgG titres 
decreased gradually during the study. This group assess-
ment covers a wide range of individual variability. In the 
PfAMA1 group the highest increase in antibody titres was 
60-fold increase reported after second vaccination. Those 
with the highest increase had the lowest baseline levels. In 
the PfAMA-1 group, MFI was significantly and negatively 
correlated with day 0 IgG titre (p =  0.002). The correla-
tion coefficient was −0.67 with 95 % CI (−0.86 to −0.31). 
In the malaria vaccine group antibody responses were not 
sustained and returned to baseline levels after 12 months.
Growth inhibition assays
GIA titres are summarized in Table 4. Baseline levels of 
GIA were high in both groups: PfAMA1 and control vac-
cines recipients had baseline GIA levels of 56 (25–44) 
and 59 (19–50), respectively. Vaccination did not change 
GIA titres resulting in day 84 GIA titres of 68 (7–64) and 
62 (19–53) for the PfAMA1 and control group, respec-
tively. GIA titres decreased slightly by day 365, with GIA 
titres of 43 (26–31) and 49 (25–36) for PfAMA1 and con-
trols, respectively.
Discussion
This study is the first evaluation of the AMA1-based 
malaria vaccine PfAMA1-FVO [25-545] adjuvanted with 
alum in malaria-experienced adults. The vaccine showed 
acceptable tolerability. Local reactions were more frequent 
in malaria vaccine groups than in the comparator group. 
Most recipients of the malaria vaccine experienced pain 
at the injection site. The incidence of injection site pain 
did not increase with subsequent administration of doses 
of the vaccine. Although swelling was often classified and 
graded based on the size of the reaction, these episodes 
of swelling were short-lived and were not associated with 
pain or with other functional impairments. There was a 
slight, non-statistical significant tendency to more adverse 
events in the control group than in the PfAMA1 group.
The safety and tolerability profile of the PfAMA1-FVO 
[25-545]/Alhydrogel® vaccine was similar to that seen in 
a previous trial of this vaccine in malaria-naïve volun-
teers [9]. Others formulations of AMA1 using different 
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Fig. 2 Anti FVO-AMA1 IgG titres. Individual data points are plotted 
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Fig. 3 Mean fold Increase in IgG titres. Mean fold Increase 
(MFI = day84/day0) in IgG titres are plotted against day 0 IgG titres 
Top panel is PfAMA-1 group. Bottom panel is Tetanus Toxoid. Dots are 
fold increase. Regression line with 95 % CI. AU arbitrary units. kAU/
mL = 1000 × AU/mL
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adjuvant system also showed acceptable tolerance pro-
file in malaria-naïve [18–20] and Malian adults [3, 4, 21]. 
Biological parameters assessed have remained within 
area normal ranges. Anaemia was a concern in AMA1-
based malaria vaccines tested in children [5, 22]. In this 
adult population, no anaemia cases were observed. A 
female participant recipient of the malaria vaccine had 
decreased levels of haemoglobin measured at two time 
points. However, these decreased levels were above the 
threshold that defined anaemia in the study population.
Antibody titres peaked 1  month after the third dose 
reaching a 3.5 fold rise. A comparable dynamic in anti-
body titres was reported in naive volunteers [9]. There is 
a very clear relation between pre-immunization titre and 
fold rise. The highest pre-titre have resulted in the low-
est fold rise. In this trial, immunization started with the 
rainy season when most malaria transmission occurs in 
the study area. However high antibody titres were not 
sustained and returned to baseline levels after 12 months. 
This could witness an absence of natural boosting. Previ-
ous trials of AMA1 using AS02, a more potent adjuvant 
system, have generated much higher antibody titres [4], 
that persisted in children more than 12 months [23].
No significant change in GIA activities were observed, 
despite the rise in IgG titres. In previous trials, serum 
from naive adults immunized with AMA-1 3D7 did not 
show good grow inhibition on heterologous (FVO) par-
asites as compared to homologous (3D7) parasites [24]. 
Interestingly the immune response elicited by AMA1 
from P. falciparum 3D7 in semi-immune adults showed 
a higher grow inhibitory activity on FVO clone than 3D7 
clone of P. falciparum [4].
The functionality of immune response induced by 
AMA-1 may not be function of the system of expres-
sion of recombinant protein used, since the AMA-1 
FVO expressed in Pichia pastoris and Escherichia coli 
has shown similar functionality in growth inhibitory 
experiments [25]. The adjuvant system might play a more 
prominent role in inducing functional antibodies.
Apical Membrane Antigen 1 is an extremely polymor-
phic protein, with more than 100 polymorphic amino 
acid sites, and in  vitro experiments and studies in both 
animals and humans have indicated some degree of 
allele-specificity in the antibody responses to genetically 
different forms of AMA-1 [26, 27]. The PfAMA1 vaccine 
is based on AMA-1 sequence from the FVO clone of P. 
falciparum and other AMA-1-based vaccines developed 
from both 3D7 and FVO [4, 10, 19, 21, 24] have given 
good immune responses and acceptable reactogenic-
ity. A phase 2b trial conducted in the same site assessed 
the efficacy of the 3D7 derived AMA-1 associated with 
AS02A did not have significant efficacy against clinical 
malaria episodes but showed high allele-specific efficacy 
against clinical malaria [28]. Vaccine allele-specific effi-
cacy depended on the degree of homology at key amino 
acid residues between the vaccine antigen and AMA-1 in 
parasites circulating at the vaccine trial site [29, 30].
The PfAMA1-FVO [25-545] malaria vaccine candi-
date clinical development was stopped after the present 
trial was completed, partly because of the potential limits 
imposed by strain specificity of protection to polymor-
phic AMA1 confirmed in human [28]. However efforts 
were pursued to overcome strain-specificity of protec-
tion. The diversity covering approach developed a cou-
ple of years before by the same team at the Biomedical 
Primate Research Centre [31–33] that developed the 
PfAMA1-FVO [25-545], is promising and have now gone 
into clinical trials in malaria endemic settings [34].
Conclusion
The PfAMA1-FVO [25-545] malaria vaccine candidate 
was safe and well tolerated in adult exposed to intense 
and seasonal malaria transmission in Mali. The vaccine 
induced high antibody response that was not however 
sustained over the malaria transmission season.
Table 3 IgG Titres to  the immunising antigen at  specified 
time points
Day PfAMA1 Tetanus toxoid
IgG (95 % CI) N IgG (95 % CI) N
Panel A. IgG titres to AMA1 FVO
0 5164 (2494–10,691) 20 9938 (4484–22,025) 20
28 13,888 (7017–27,484) 20 10,475 (4892–22,428) 20
56 14,954 (7923–28,222) 20 9192 (4103–20,591) 19
84 17,584 (9889–31,267) 19 8744 (4184–18,276) 18
140 14,048 (7808–25,275) 20 12,793 (7187–22,773) 20
364 6925 (3295–14,555) 19 6551 (2896–14,818) 16
Panel B. Titre changes following vaccination (fold increase)
0 1 20 1 20
28 2.69 (1.73–4.18) 20 1.05 (0.87–1.28) 20
56 2.90 (1.87–4.48) 20 0.93 (0.70–1.25) 19
84 3.53 (2.30–5.42) 19 1.07 (0.72–1.58) 18
140 2.72 (1.88–3.94) 20 1.29 (0.86–1.93) 20
364 1.46 (1.02–2.09) 19 0.89 (0.61–1.28) 16
Table 4 GIA titres at 10 mg/mL IgG in vaccinated and con-
trol volunteers
Day PfAMA1 Malaria Vaccine Tetanus toxoid vaccine
N GIA (95 % CI) N GIA (95 % CI)
0 20 56 (25–44) 20 59 (19–50)
84 19 68 (7–64) 18 62 (19–53)
365 19 43 (26–31) 17 49 (25–36)
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